Private equity-backed nutraceuticals company under consideration for takeover by KKR, indicates negotiations for significant share ownership.
In the bustling world of private equity, KKR & Co, a global powerhouse, is currently in advanced discussions to acquire a majority stake in an Indian nutraceutical ingredients manufacturer. This potential acquisition is taking place amidst concerns over trade tariffs imposed by US President Donald Trump on Indian imports, which could potentially impact the transaction environment.
Despite these trade tariff concerns, the fact that KKR is a frontrunner in acquiring the majority stake suggests that negotiations are actively ongoing. However, no specific details about the name of the Indian company or the deal valuation have been disclosed in the latest publicly available reports.
Meanwhile, other PE/VC firms are weighing a bet on OmniActive, as TA Associates plans an exit. The exact identity of the Indian nutraceutical ingredients maker and the specific terms of the transaction, such as the purchase price, remain undisclosed.
Elsewhere in the industry, UAE-based PE firm Gulf Capital has partially exited from a fertility chain, though the exact terms of the exit, including the sale price, have not been disclosed.
It's worth noting that this flurry of activity comes as PE/VC firms have cashed in on the stock market rally, minting $3 billion via exits within a month. However, the identity of these firms and the strategics involved, such as Panasonic, Coinbase, Accion Labs, Ratnadeep Retail, and IndoSpace, are not specified.
As of late July 2025, KKR & Co remains engaged in advanced discussions to acquire the Indian nutraceutical ingredients company, with trade tariffs by the US administration noted as a background consideration but not a confirmed impediment. The progress of the deal, as well as the other transactions mentioned, continues to be a fascinating development in the dynamic world of private equity.
The active negotiations of KKR & Co for the acquisition of a majority stake in an Indian nutraceutical ingredients manufacturer indicate an involvement in financially significant dealings. Despite ongoing concerns over trade tariffs, KKR's position as a frontrunner suggests the deal is moving forward, albeit without disclosed details about the involved company or valuation.
